High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

References

• SterneJAHernanMALedergerberBEggerMSwiss HIV Cohort StudyLong-term effectiveness of potent anti-retroviral therapy in preventing AIDS and death: a prospective cohort studyLancet2005366948337838416054937
   PubMed Web of Science ®Google Scholar
• BorJHerbstAJNewellMLBärnighausenTIncreases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatmentScience2013339612296196523430655
   PubMed Web of Science ®Google Scholar
• JinYLiuZWangXA systematic review of cohort studies of the quality of life in HIV/AIDS patients after anti-retroviral therapyInt J STD AIDS2014251177177724598977
   PubMed Web of Science ®Google Scholar
• KumarasamyNSolomonSChaguturuSKThe changing natural history of HIV disease: before and after the introduction of generic anti-retroviral therapy in southern IndiaClin Infect Dis200541101525152816231268
   PubMed Web of Science ®Google Scholar
• KatzensteinDAHIV RNA and genotype in resource-limited settings: can we do better?Clin Infect Dis201458111011224076967
   PubMed Web of Science ®Google Scholar
• RupérezMPouCMaculuveSDeterminants of virological failure and anti-retroviral drug resistance in MozambiqueJ Antimicrob Chemother20157092639264726084302
   PubMed Web of Science ®Google Scholar
• World Health OrganizationWHO Global Strategy for the Surveillance and Monitoring of HIV Drug Resistance2012 Available from: http://apps.who.int/iris/bitstream/10665/77349/1/9789241504768_eng.pdfAccessed September 11, 2015
   Google Scholar
• HosseinipourMCGuptaRKVan ZylGEronJJNachegaJBEmergence of HIV drug resistance during first- and second-line anti-retroviral therapy in resource limited settingsJ Infect Dis2013207Suppl 2S49S5623687289
   PubMed Web of Science ®Google Scholar
• ScherrerAUvon WylVYangWLand the Swiss HIV Cohort StudyEmergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland – a 15 year prospective cohort analysisClin Infect Dis201662101310131726962075
   PubMed Web of Science ®Google Scholar
• HamersRLSigaloffKCWensingAMPharmAccess African Studies to Evaluate Resistance (PASER)Patterns of HIV-1 drug resistance after first-line anti-retroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategiesClin Infect Dis201254111660166922474222
   PubMed Web of Science ®Google Scholar
• HuntGMLedwabaJBassonAESurveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005–2009Clin Infect Dis201254Suppl 4S334S33822544199
   PubMed Web of Science ®Google Scholar
• WoodEMontanerJSTime to get serious about HIV anti-retroviral resistanceLancet Infect Dis2011111072372421958572
   PubMed Web of Science ®Google Scholar
• LiaoLXingHShangHThe prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in ChinaJ Acquir Immune Defic Syndr201053Suppl 1S10S1420104099
   PubMed Web of Science ®Google Scholar
• HattoriJShiinoTGatanagaHTrends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in JapanAntiviral Res2010881727920692295
   PubMed Web of Science ®Google Scholar
• KimMHSongJEAhnJYHIV anti-retroviral resistance mutations among anti-retroviral treatment-naive and -experienced patients in South KoreaAIDS Res Hum Retroviruses2013291617162023952717
   PubMed Web of Science ®Google Scholar
• SungkanuparphSSukasemCKiertiburanakulSPasomsubEChantratitaWEmergence of HIV-1 drug resistance mutations among anti-retroviral-naïve HIV-1-infected patients after rapid scaling up of anti-retroviral therapy in ThailandJ Int AIDS Soc20121511222410286
   PubMed Web of Science ®Google Scholar
• LaiCCHungCCChenMYTrends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line anti-retroviral therapy in TaiwanJ Antimicrob Chemother20126751254126022302562
   PubMed Web of Science ®Google Scholar
• LaiCCLiuWCFangCTTransmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in TaiwanJ Antimicrob Chemother201671122623426404079
   PubMed Web of Science ®Google Scholar
• WensingAMCalvezVGünthardHF2015 Update of the Drug resistance Mutations in HIV-1Top Antivir Med201523413214126713503
   PubMedGoogle Scholar
• UgbenaRAberle-GrasseJDialloKVirological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in NigeriaClin Infect Dis201254Suppl 4S375S38022544206
   PubMed Web of Science ®Google Scholar
• TambuyzerLNijsSDaemsBPicchioGVingerhoetsJEffect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirineJ Acquir Immune Defic Syndr2011581182221637112
   PubMed Web of Science ®Google Scholar
• VingerhoetsJNijsSTambuyzerLHoogstoelAAndersonDPicchioGSimilar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systemsAntivir Ther20121781571157922869341
   PubMed Web of Science ®Google Scholar
• NijhuisMvan MaarseveenNMLastereSA novel substrate-based HIV-1 protease inhibitor drug resistance mechanismPLoS Med200741e3617227139
   PubMed Web of Science ®Google Scholar
• LarrouyLChazallonCLandmanRand the ANRS 127 Study GroupGag mutations can impact virological response to dual-boosted protease inhibitor combinations in anti-retroviral-naïve HIV-infected patientsAntimicrob Agents Chemother20105472910291920439606
   PubMed Web of Science ®Google Scholar
• FunAWensingAMVerheyenJNijhuisMHuman immunodeficiency virus gag and protease: partners in resistanceRetrovirology201296322867298
   PubMed Web of Science ®Google Scholar
• AjoseOMookerjeeSMillsEJBoulleAFordNTreatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysisAIDS201226892993822313953
   PubMed Web of Science ®Google Scholar
• SaravananSVidyaMBalakrishnanPViremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern IndiaClin Infect Dis2012547995100022323567
   PubMed Web of Science ®Google Scholar
• ThaoVPQuangVMDayJNHigh prevalence of PI resistance in patients failing second-line ART in VietnamJ Antimicrob Chemother201671376277426661398
   PubMed Web of Science ®Google Scholar
• MaigaAIFofanaDBCisseMCharacterization of HIV-1 anti-retroviral drug resistance after second-line treatment failure in Mali, a limited-resources settingJ Antimicrob Chemother201267122943294822888273
   PubMed Web of Science ®Google Scholar
• RawizzaHEChaplinBMeloniSTAccumulation of protease mutations among patients failing second-line anti-retroviral therapy and response to salvage therapy in NigeriaPLoS One20138e7358224069209
   PubMed Web of Science ®Google Scholar
• WeintrobACFiebergAMAganBKIncreasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAARTJ Acquir Immune Defic Syndr2008491404718667932
   PubMed Web of Science ®Google Scholar
• GrabarSKousignianISobelAImmunologic and clinical responses to highly active anti-retroviral therapy over 50 years of age. Results from the French Hospital Database on HIVAIDS200418152029203815577624
   PubMed Web of Science ®Google Scholar
• MollanKDaarESSaxPEand the AIDS Clinical Trials Group Study A5202 TeamHIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease statusJ Infect Dis2012206121920193023148287
   PubMed Web of Science ®Google Scholar
• BartlettJARibaudoHJWallisCLLopinavir/ritonavir mono-therapy after virologic failure of first-line anti-retroviral therapy in resource-limited settingsAIDS201226111345135422441252
   PubMed Web of Science ®Google Scholar
• OrrellCWalenskyRPLosinaEHIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community anti-retroviral therapy programmeAntivir Ther20091452353119578237
   PubMed Web of Science ®Google Scholar
• SigaloffKCRamatsebeTVianaRde WitTFWallisCLStevensWSAccumulation of HIV drug resistance mutations in patients failing first-line anti-retroviral treatment in South AfricaAIDS Res Hum Retroviruses201228217117521819219
   PubMed Web of Science ®Google Scholar
• DurantJClevenberghPHalfonPDrug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trialLancet199935391712195219910392984
   PubMed Web of Science ®Google Scholar
• BaxterJDMayersDLWentworthDNA randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDSAIDS2000149F83F9310894268
   PubMed Web of Science ®Google Scholar
• FalloonJTime to genotype for selection of antiretroviral regimens in previously treated patients?Lancet199935391712173217410392975
   PubMed Web of Science ®Google Scholar